Clinical Implications of Human Papillomavirus in Head and Neck Cancers

Carole Fakhry and Maura L. Gillison

From the Departments of Viral Oncology, Aerodigestive Malignancy, and Cancer Prevention and Control, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and the Departments of Epidemiology and Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

Submitted February 9, 2006; accepted February 27, 2006.

Supported in part by National Institute for Dental and Craniofacial Research Grant No. DE016631-02.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Address reprint requests to Maura L. Gillison, MD, PhD, Cancer Research, Building I, Room G91, 1650 Orleans St, Baltimore, MD 21231; e-mail: gilima@jhmi.edu.

© 2006 by American Society of Clinical Oncology. All rights reserved.

J Clin Oncol 24:2606-2611. © 2006 by American Society of Clinical Oncology

ABSTRACT

Human papillomavirus (HPV) is now recognized to play a role in the pathogenesis of a subset of head and neck squamous cell carcinomas (HNSCCs), particularly those that arise from the lingual and palatine tonsils within the oropharynx. High-risk HPV16 is identified in the overwhelming majority of HPV-positive tumors, which have molecular-genetic alterations indicative of viral oncogene function. Measures of HPV exposure, including sexual behaviors, seropositivity to HPV16, and oral, high-risk HPV infection, are associated with increased risk for oropharyngeal cancer. HPV infection may be altering the demographics of HNSCC patients, as these patients tend to be younger, nonsmokers, and nondrinkers. There is sufficient evidence to conclude that a diagnosis of HPV-positive HNSCC has significant prognostic implications; these patients have at least half the risk of death from HNSCC when compared with the HPV-negative patient. The HPV etiology of these tumors may have future clinical implications for the diagnosis, therapy, screening, and prevention of HNSCC.

INTRODUCTION

Oral human papillomavirus (HPV) infection, like alcohol and tobacco, is now recognized to play a role in the pathogenesis of head and neck squamous cell carcinomas (HNSCCs).1-7 HPVs are DNA viruses with a specific tropism for squamous epithelia, and more than 120 different HPV types have been isolated to date. Low-risk HPVs, such as HPV6 and -11, induce benign hyperproliferations of the epithelium such as papillomas or warts. By contrast, high-risk, oncogenic types (eg, HPV16, -18, -31, -33, -35) are defined by their strong epidemiologic association with cervical cancer.8 The prototypic high-risk types -16 and -18 are capable of transforming epithelial cells derived from both the genital and upper respiratory tracts.9 The transforming potential of high-risk HPVs is largely a result of the function of two viral oncoproteins, E6 and E7, which functionally inactivate two human tumor-suppressor proteins, p53 and pRb, respectively.10 Expression of high-risk HPV E6 and E7 results in cellular proliferation, loss of cell cycle regulation, impaired cellular differentiation, increased frequency of spontaneous and mutagen-induced mutations, and chromosomal instability.10

HPV DNA PRESENCE AND EXPRESSION IN OROPHARYNGEAL CANCERS

Infection by a high-risk HPV type is now known to be necessary, although insufficient, for the development of cervical cancer. In contrast to cervical cancer, in HNSCC, HPV appears to play a pathogenic role for only a subset.1,2,6,11-18 It is clear that continued expression of the viral oncogenes is necessary for histopathologic progression and the malignant phenotype of an HPV-associated tumor19-22: HPV’s are not known to work by a hit-and-run mechanism. Therefore, demonstration of HPV genomic DNA in tumors is essential for HPV to play a role in the pathogenesis of a tumor.23 In a recent meta-analysis, HPV genomic DNA was detected in approximately 26% of all HNSCC by sensitive polymerase chain reaction (PCR) -based methods.24 However, data are most strong and consistent for HPV presence in oropharyngeal cancers. In the majority of studies, 50% or more of oropharyngeal tumors contained the HPV genome.1,2,11,15,17,18,25-30 In a recent multinational study conducted by the International Agency for Research on Cancer (IARC), only 18% of oropharyngeal tumors were HPV positive, indicating that this proportion likely varies by geography.31 Regardless of the study population, high-risk HPV16 accounts for the overwhelming majority (90% to 95%) of HPV-positive tumors, whereas other high-risk types -31, -33, and -35 account for the minority.24,31 For oropharyngeal tumors, viral HPV DNA has been specifically localized to tumor cell nuclei,2,6 is frequently integrated,2,4,6,32-36 and is transcriptionally active.2,4,5,11,27,32,34,37 Furthermore, HPV is present in high copy number in tumor cell nuclei of in situ, invasive, and metastatic disease and absent in adjacent normal tissue.38 These data indicate that HPV infection is specific to tumor cell nuclei and that infection precedes histopathologic
progression of the tumor. Equivalent data are not available for non-oro-pharyngeal tumors. For instance, HPV has not been shown to have an etiologic association with oral tongue cancers diagnosed at any age. Although HPV can infect the epithelium of the upper aerodigestive tract in general, the tonsil appears uniquely susceptible to transformation by the virus. As for the transformation zone of the cervix, the reason for this anatomic site specificity for transformation is unknown.

A role for HPV in oropharyngeal tumors is further substantiated by distinct molecular genetic alterations in HPV-positive versus HPV-negative tumors. As for many cancers, inactivation of the p53 and pRb pathways is a common event in the molecular progression of HNSCC. However, inactivation occurs by different mechanisms in HPV-positive and -negative tumors. In HPV-positive HNSCC, genetic alterations are reflective of viral oncogene function. For instance, HPV-positive tumors tend to have wild-type p53, because p53 is functionally inactivated by viral E6 oncoprotein. 

By contrast, HPV-negative tumors have specific p53 mutations demonstrated to be induced by carcinogens in tobacco smoke. 

As another example, pRb function is inactivated by viral E7 protein in the HPV-positive tumor, but in HPV-negative tumors, the pRb pathway is altered by other mechanisms, including amplification of cyclin D and inactivation of p16. More complex differences in regions of chromosomal loss and gain have been demonstrated in HPV-positive versus -negative tumors through techniques such as comparative genomic hybridization and microsatellite analysis.

### Clinical Characteristics of the HPV-Positive Patient

In addition to molecular-genetic distinctions, HPV affects the demographics, clinical presentation, and histopathology of the HNSCC patient. Patients with HPV-positive HNSCC tend to be younger by approximately 5 years, on average, when compared with HPV-negative HNSCC patients. With regard to sex, men appear to be at equal risk to women. It is clear that the majority of HPV-positive tumors arise largely from the lingual and palatine tonsils in the oropharynx, compared with other anatomic sites of the head and neck. Although some studies have found associations between advanced TNM stage at presentation and HPV positivity, this finding has been somewhat inconsistent. Histopathologically, HPV-positive tumors tend to have a poorly differentiated and frequently basaloid histology.

### Risk Factors for HPV-Positive HNSCC

The HPV-positive patient also appears to be distinct from the HPV-negative patient with regard to alcohol and tobacco exposure history. HPV-positive HNSCC is more likely than HPV-negative HNSCC to occur in the nonsmoker and nondrinker. In a study restricted to patients with oropharyngeal cancers, nonsmokers were approximately 15-fold more likely to have a diagnosis of HPV-positive HNSCC than smokers. Similarly, several studies have reported an inverse association between HPV status and alcohol use. Although evidence suggests that HPV is associated with cancers in nonsmokers and nondrinkers, the degree to which oral HPV infection may combine with tobacco and/or alcohol use to increase risk of cancer is currently unclear, with some studies suggesting a synergistic effect with tobacco or alcohol, whereas others have found no such synergy.

Numerous case-control studies of cervical cancer patients have indicated that HPV infection is predominantly sexually transmitted. Certain sexual behaviors, such as a high number of sexual partners, are associated with increased risk of cervical cancer because they serve as surrogate markers for the probability that an individual has been exposed to HPV. Consistent with this literature, several case-control studies have reported certain sexual behaviors to elevate risk of HNSCC. Risk factors among men include young age at first intercourse, number of sexual partners, and a history of genital warts. Risk is elevated among women with a high number of sexual partners. Furthermore, specific sexual behaviors have been more strongly associated with risk of an HPV-positive tumor, including a history of performing oral sex and oral-anal contact.

Direct measures of HPV exposure and infection have also been associated with risk of oral cancers. Seropositivity to the HPV16 viral capsid protein confers a two- to three-fold increase in risk for HNSCC. In case-control studies, the presence of an oncogenic, oral HPV infection has been associated with a six-fold increase in risk for oral cancer. Risk estimates are stronger when restricted to oropharyngeal cancer. In a recent study conducted in Sweden, oral infection by a high-risk HPV type was demonstrated to dramatically elevate odds for oropharyngeal cancer (odds ratio, 230; 95% CI, 44 to 1,200), after adjustment for alcohol and tobacco. In a nested case-control study conducted in Norway, HPV16-seropositive individuals had a greater than 14-fold increase in risk of subsequent oropharyngeal cancer when compared with seronegative individuals. This study was particularly important because it demonstrated that HPV exposure preceded development of clinical disease.

Although natural history studies have not been conducted, it is presumed that oral HPV infection precedes development of an HPV-positive HNSCC. Therefore, risk factors for oral HPV infection are likely, by extension, to be risk factors for HPV-positive HNSCC. Oral HPV infection has recently been associated with sexual behavior, in particular with number of oral sex partners. Other factors associated with elevated risk of oral HPV infection include increasing age, male sex, history of sexually transmitted disease, HIV infection, and severity of immunosuppression.

Because the majority of tonsillar cancers are HPV positive, risk for tonsillar cancer may be a reasonable surrogate for risk of an HPV-associated HNSCC. Individuals at increased risk of tonsillar cancer include those with a history of HPV-associated malignancy, women over the age of 50 years with a history of in situ cervical cancer, and husbands of women with in situ and invasive cervical cancer. HPV-seropositive and immunosuppressed transplant patients have also been recognized to be at increased risk for tonsillar and oropharyngeal cancer, as well as all other HPV-associated malignancies. A recent report has suggested that the 500- to 700-fold increase in risk of HNSCC among patients with Fanconi anemia may be attributable to an increased genetic susceptibility to HPV-mediated tumorigenesis.

As stated previously, HPV-positive patients tend to be younger than patients with HPV-negative tumors. Consistent with this finding, high-risk sexual behaviors were more prevalent among HNSCC patients younger than 55 years when compared with those older than 55 years in a recent case-control study. In the United States, herpes
simplex-2 seroprevalence, a validated marker for high-risk sexual behaviors, increased by 30% between the periods 1976 through 1980 to 1988 through 1994, and the relative increase was more pronounced as age declined.67 Studies from Scandinavia68 indicate that HPV16 seroprevalence also significantly increased over time, between 1968 and 1990. According to Surveillance, Epidemiology, and End Results (SEER) data, the incidence of base-of-tongue and tonsil cancers increased by 2.1% and 3.9% per year, respectively, from 1973 to 2001 among white men and women ages 20 to 44 years, whereas the incidence at other sites declined.69,70 Additional analysis indicates tonsillar cancer incidence increased annually by approximately 2% to 3% among African American and white men younger than 60 years through 1998.69,71 These data are consistent with a role for HPV in the etiology of tonsillar cancers. HPV may therefore be having a significant impact on the demographics of the HNSCC patient.

It is now clear from numerous lines of evidence that individuals exposed to HPV are at increased risk for oropharyngeal cancer. However, data are currently insufficient to estimate with precision the magnitude of this risk. The potential utility of HPV detection for oral cancer screening is largely unexplored. Because of the absence of this data, there are currently no commercially available, US Food and Drug Administration–approved tests for HPV serology or for detection of oral HPV infection.

**CLINICAL SIGNIFICANCE OF AN HPV-POSITIVE TUMOR**

HPV detection may have future implications for the diagnosis, prognosis, therapeutics, and prevention of HNSCC. For diagnostic purposes, HPV detection in cervical lymph nodes of patients presenting with an occult primary may be used to establish with high specificity, the location of the primary within the oropharynx.68 Tonsillectomy has been shown in retrospective analyses to identify the primary site of cervical metastases as the contralateral72,73 or ipsilateral74,75 tonsil in approximately 30% and 10% of cases, respectively.

With regard to prognosis, patients with HPV-positive tumors have improved prognosis when compared with patients with HPV-negative tumors in the majority of studies.2,15,17,28,35,76-78 Studies to date have suggested that HPV-positive patients may have as much as 60% to 80% reduction in risk of dying from their cancer when compared with the HPV-negative patient.2,27,78 Negative studies may be explained by inadequate sample size, follow-up time, and residual confounding by other prognostically significant variables.12-14,17,18,40,45,51 The reason for the improved survival is unclear; however, improved radiation responsiveness, immune surveillance to viral antigens, and the absence of field cancerization in these patients who tend to be nonsmokers, have been postulated.28,35,79,80 In addition, E6-related degradation of p53 in HPV-positive cancers may be functionally inequivalent to HPV-negative p53 mutations,81,82 and therefore, HPV-positive tumors may have an intact apoptotic response to radiation and chemotherapy.79,83

Possible therapeutic implications of an HPV-positive diagnosis are an active area of investigation. This includes selection of patients for organ preservation therapy, which may be more successful in patients with HPV-HNSCC. The impact of HPV presence on oropharyngeal organ preservation is currently being evaluated in an Eastern Cooperative Oncology Group protocol that has met its target enrollment. A clinical trial of an HPV16-specific therapeutic vaccine is also currently actively recruiting patients at The Johns Hopkins Hospital (J.H.H.; Baltimore, MD). The vaccine is administered in the adjuvant setting and is intended to enhance the cytotoxic T-cell response to the HPV16 oncoproteins.84 With regard to prevention, a prophylactic vaccine composed of the HPV16 viral capsid protein has...
recently been shown to prevent persistent HPV16 infection and the development of cervical dysplasia in phase three randomized controlled trials.85,86 US Food and Drug Administration approval is anticipated within the next few years. However, the clinical trials have not included an evaluation of the impact of the vaccine on oral HPV infection. Data on oral HPV infections in the setting of immunization are limited to canine and hamster models, which have shown a protective effect and a reduction in the development of HPV-related oral lesions.87,88 The vaccine does have the potential to have a greater impact on HNSCC incidence than for cervical cancer incidence, given that the current vaccines are largely targeted to HPV16.

HOW TO MAKE THE DIAGNOSIS OF HPV-HNSCC

The diagnosis of HPV-HNSCC should be considered in all squamous cell carcinomas that arise from the lingual and palatine tonsils. Suspicion should be high for cancers in nonsmokers and nondrinkers, patients with basaloid or poorly differentiated histology, the young patient, the immunosuppressed patient and the patient with Fanconi anemia. The only clinically useful test to confirm the diagnosis of HPV is in situ hybridization (ISH), and is currently only available at a limited number of tertiary referral centers. The JHH Pathology Department uses the GenPoint system (DAKO, Carpinteria, CA) with a DAKO HPV16 probe with a sensitivity of one to two copies of integrated HPV16.89 (Tumor testing is available at JHH http://pathology.jhu.edu/labservices/hpv.cfm.) p16 immunohistochemistry may serve as a reasonable surrogate marker for high-risk HPV because strong correlations have been found between diffuse nuclear and cytoplasmic p16 staining. HPV DNA by ISH8 and real-time PCR29 (Fig 1). For research purposes only, real-time PCR can be performed on microdissected tumor DNA normalized to a single-copy human gene to demonstrate one or more viral copies per tumor cell.29,90,91 Possible future diagnostic tests that would likely have a higher specificity but low sensitivity for a diagnosis of HPV-associated HNSCC will include the detection of HPV16 DNA in plasma,92 fluorescence ISH or ISH on papanicolou smears obtained directly from tumors,93 and HPV16 E6 and E7 seroreactivity.94,95 These are all active areas of investigation.

CONCLUSION

Strong epidemiologic and molecular data support the conclusion that HPV is responsible for a unique subset of HNSCCs. Sexually acquired oral HPV infection may alter the epidemiology and demographic patterns of tonsillar squamous cell carcinomas.6,9,3 Recent data from our laboratory support the use of p16 immunohistochemistry as a reasonable surrogate marker for high-risk HPV in head and neck cancers.16,96-98 The immunohistochemical staining patterns of tonsillar squamous cell carcinomas are a unique subset of HPV-positive HNSCC.99-101 HPV16 is the most common HPV type associated with head and neck cancer: Clinical correlates and survival. Clin Cancer Res 2:755-762, 1996


Authors’ Disclosures of Potential Conflicts of Interest
The authors indicated no potential conflicts of interest.

Author Contributions

Conception and design: Maura L. Gillison
Financial support: Maura L. Gillison
Administrative support: Carole Fakhry
Manuscript writing: Carole Fakhry, Maura L. Gillison
Final approval of manuscript: Maura L. Gillison